High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008

Autor: Bénédicte Brichard, Ian Judson, Heribert Juergens, Richard B. Womer, Uta Dirksen, Ian Lewis, Line Claude, Cyril Lervat, Ruth Ladenstein, Michael Paulussen, Peter Hauser, Jean Marc Guinbretiere, Perrine Marec-Berard, Neyssa Marina, Natalie Gaspar, Odile Oberlin, Hans Gelderblom, Keith Wheatley, R. Lor Randall, Bernadette Brennan, Robert E. Goldsby, Lars Hjorth, Douglas S. Hawkins, Katherine A. Janeway, Thomas Kuehne, Alan W. Craft, Claude Linassier, Holcombe E. Grier, Richard Gorlick, Jarmila Kruseova, Gwénaël Le Teuff, Nathalie Cozic, Susanne Amler, Bruce Morland, Marie-Cécile Le Deley, Henk van den Berg, Jeremy Whelan, H. Pacquement, Andreas Ranft, Mark Krailo, Vivek A Bhadri, Stephen L. Lessnick

Publikováno v: Journal of clinical oncology, Vol. 37, no.34, p. 3192-3202 (2019)
Journal of clinical oncology, 37(34), 3192-3202. American Society of Clinical Oncology
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 37, iss 34

PURPOSE The R2Pulm trial was conducted to evaluate the effect of busulfan-melphalan high-dose chemotherapy with autologous stem-cell rescue (BuMel) without whole-lung irradiation (WLI) on event-free survival (main end point) and overall survival, com

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::247ce45bf423d9d558791842a18599e9
https://hdl.handle.net/2078.1/239523